bpc-157 human clinical trials safety regulatory status What do we know about 'research only' peptides? Q&A with expert Stuart Phillips bpc-157 human clinical trial evidence

IGF-1 is posited to be the main mediator of GHs anabolic actions

OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship

By supporting better sleep quality, DSIP may indirectly support cognitive function sharper memory, clearer thinking, better attentional capacity

However, retatrutide also carries higher GI side effect rates at these doses